Concepedia

Akintunde Bello

AB

41

Publications

2K

Citations

24

H-Index

1992

Active since

Affiliations

Bristol-Myers Squibb (United States)(Current)

Pfizer (United States)

Bristol-Myers Squibb (Germany)

Pfizer (Italy)

Bristol-Myers Squibb (Sweden)

Akintunde Bello is an author at Bristol-Myers Squibb (United States) specializing in medicine, pharmacotherapy, and pharmacology.

ORCID

Top concepts

Publications per year

1992–2024

41

Publications

41

Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma

Robert J. Motzer, Thomas E. Hutson, Mark R. Olsen et al. · Journal of Clinical Oncology · 2012 · 275 citations · Full text

Assessment of nivolumab benefit–risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors

Xiaochen Zhao, Satyendra Suryawanshi, Matthew Hruska et al. · Annals of Oncology · 2017 · 231 citations · Full text

Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer

Georgina V. Long, Scott S. Tykodi, Jeffrey Schneider et al. · Annals of Oncology · 2018 · 200 citations · Full text

Polymeric Nanoparticles for Increased Oral Bioavailability and Rapid Absorption Using Celecoxib as a Model of a Low-Solubility, High-Permeability Drug

Michael M. Morgen, Corey Bloom, Ron Beyerinck et al. · Pharmaceutical Research · 2011 · 147 citations · Full text

Nivolumab Exposure–Response Analyses of Efficacy and Safety in Previously Treated Squamous or Nonsquamous Non–Small Cell Lung Cancer

Feng Yan, Xiaoning Wang, Gaurav Bajaj et al. · Clinical Cancer Research · 2017 · 97 citations · Full text

Rows per page

1–5 of 41